Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,902 | $1,243 | $933 | $702 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Cost of Goods Sold | $319 | $150 | $140 | $97 |
| Gross Profit | $1,583 | $1,093 | $793 | $605 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| R&D Expenses | $805 | $877 | $877 | $771 |
| G&A Expenses | $558 | $453 | $437 | $283 |
| SG&A Expenses | $558 | $482 | $451 | $283 |
| Sales & Mktg Exp. | $0 | $29 | $15 | $0 |
| Other Operating Expenses | $2 | $2 | $1 | $11 |
| Operating Expenses | $1,365 | $1,361 | $1,329 | $1,065 |
| Operating Income | $218 | -$268 | -$536 | -$460 |
| % Margin | 11.5% | -21.5% | -57.5% | -65.5% |
| Other Income/Exp. Net | $43 | -$252 | -$154 | $41 |
| Pre-Tax Income | $261 | -$520 | -$690 | -$419 |
| Tax Expense | $26 | $16 | $14 | -$0 |
| Net Income | $235 | -$536 | -$703 | -$419 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS | 2.47 | -5.8 | -8.03 | -5.15 |
| % Growth | 142.6% | 27.8% | -55.9% | – |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| Weighted Avg Shares Out | 95 | 92 | 88 | 81 |
| Weighted Avg Shares Out Dil | 108 | 92 | 88 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $86 | $28 | $1 |
| Interest Expense | $18 | $22 | $53 | $64 |
| Depreciation & Amortization | $54 | $59 | $55 | $38 |
| EBITDA | $333 | -$439 | -$582 | -$317 |
| % Margin | 17.5% | -35.3% | -62.4% | -45.2% |